CClinicalTrials.gg
TerminatedNCT02045329Updated Oct 17, 2018

Impact of Mupirocin Decolonization on the Nasal Microbiome

An observational study in Nasal Colonization With Staph Aureus, sponsored by VA Eastern Colorado Health Care System. Terminated at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by VA Eastern Colorado Health Care System · Observational

Why this study was terminated
Logistically unable to recruit subjects
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
1
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The normal bacteria that inhabit the human nose, also known as the nasal microbiome, may serve as a host defense mechanism against colonization and infection by Staphylococcus aureus, including methicillin resistant S. aureus (MRSA). Mupirocin is a topical antibacterial agent that may be used to clear nasal colonization with S. aureus, and reduce risk of S. aureus infection. The impact of mupirocin on the normal nasal microbiome is not known. We hypothesize that the nasal microbiome is changed by mupirocin. Our study aims to define the nasal microbiome before and after decolonization therapy with mupirocin.

Read the detailed description

A. Outcome Measures: This is essentially a descriptive study. We will define the nasal microbiota before and after decolonization therapy with mupirocin.

B. Description of Population to be Enrolled: Patients at VA-Denver who are starting a course of nasal mupirocin therapy for S. aureus decolonization will be enrolled. The common indications for decolonization therapy are preparation for joint replacement surgery and to facilitate removing patient from isolation for a prolonged stay on the rehabilitation service. Written informed consent will be obtained.

C. Study design and research methods: A nasal swab will be obtained just prior to initiation of mupirocin therapy, within 48 hours of the completion of mupirocin therapy, one week, two weeks, four weeks, eight weeks, and 16 weeks following the completion of mupirocin therapy. The swab will be inserted into one nare and rotated for 3 seconds. The procedure will be repeated on the other nare. The two heads will be refrigerated immediately, and held at 2-5o C until they can be placed into sterile micro tubes for storage at -80o C. A separate swab will be passed through the mouth and rubbed over the tonsils and posterior oropharynx , and stored in the same fashion.

Broad-Range PCR and High throughput DNA Sequencing PCR amplification and sequencing of rRNA genes will follow our previously published protocol (13). In brief, DNA lysates are subjected to PCR with pan-bacterial 16S rDNA rDNA primers, which yields libraries of PCR amplicons representative of all bacteria or fungi in a specimen (14). Triplicate PCR reactions will be performed and amplicons pooled for each sample. Poisoning controls spiked with bacterial (e.g. Bacillus subtilis) genomic DNA will be assayed to detect the presence of PCR inhibitors in template DNA preparations; although not typically a problem with nasal swabs, inhibitory samples will be purified by ethanol precipitation and then resubmitted for PCR. PCR amplicon libraries will be sequenced using the high-throughput Illumina MiSeq personal sequencing platform. which is available through the University of Colorado's Division of Infectious Diseases. This platform can generate 5-20x106 DNA sequences in a single instrument run with mean read lengths \~450 nts. The primers used for broad-range PCR include unique barcoded sequences in order to simultaneously sequence multiple amplicon libraries in a single instrument run (15). We will construct and sequence libraries from 100 specimens (50 persistent MRSA carriers [cases] and 50 non-carriers [controls]) to a depth of >50,000 high-quality sequencing reads per specimen. Our preliminary study indicates that this depth of coverage will represent a complete survey of the nares microbiota for each specimen.

Sequence Analysis Microbes present in specimens will be identified through use of the Naïve Bayesian Classifier Tool (16) of the Ribosomal Database Project (17). To reduce the overall complexity of the datasets, similar rDNA sequences will be clustered into operational taxonomic units (OTUs) by clustering sequences based on taxonomic assignments. Data matrices are then assembled that tabulate the frequency of each OTU in a sample. Sampling coverage for each amplicon library will be estimated (18-20) and additional sequences screened if coverage is less than 95%. All sequences will be deposited into GenBank for public use.

Validation of candidate microorganisms Microbes identified through broad-range rDNA analysis as potentially impacting S. aureus colonization will be further evaluated based on targeted QPCR measurements. Based on our preliminary results and previously published studies that suggest their interference with S. aureus growth, both S. epidermidis, (femA) and Corynebacterium spp., (rpoB PCR) will be enumerated by Q-PCR (Table, below). Primer sets for Q-PCR assays of novel microbial groups will be designed for detection of rDNA operons (i.e. 16S-ITS-23S genes) through the ARB software package (21). In the case of previously recognized microbial groups and/or species, PCR primer sets may be identified by literature search.

02

Conditions studied

  • Nasal Colonization With Staph Aureus

Keywords

  • Staphylococcus aureus, mupirocin, decolonization
03

In context

Lead sponsor

VA Eastern Colorado Health Care System is the lead sponsor of 49 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus

Eligibility criteria

Inclusion Criteria: - Patients at VA-ECHCS who are starting a course of nasal mupirocin therapy for S. aureus decolonization

Exclusion Criteria:

Age \< 18 years Pregnant women Prisoners Decisionally challenged subjects

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
1 participant (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Staphylococcus aureus nasal carriers

    Patients who are treated with mupirocin to clear nasal colonization with Staphylococcus aureus

06

What researchers measure

Primary outcomes

  1. Nasal microbiome changes with mupirocin

    This is a descriptive study. We will define the nasal microbiota before and after decolonization therapy with mupirocin.

    Time frame: 16 weeks

Secondary outcomes

  1. Recurrence of S. aureus colonization

    We will look at differences in the nasal microbiome of subjects who realpse with colonization and those who remain free of S. aureus colonization.

    Time frame: 16 weeks

07

Study locations

1 site
  • Veterans Affairs Eastern Colorado Healthcare System
    Denver, Colorado 80220, United States
08

References and documents

Publications

  • Frank DN, Feazel LM, Bessesen MT, Price CS, Janoff EN, Pace NR. The human nasal microbiota and Staphylococcus aureus carriage. PLoS One. 2010 May 17;5(5):e10598. doi: 10.1371/journal.pone.0010598. PubMed 20498722 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02045329
Lead sponsor
VA Eastern Colorado Health Care System
Responsible party
Sponsor
First posted
Jan 24, 2014
Start date
Oct 2013
Primary completion
Jun 5, 2015
Completion
Jun 5, 2015
Last update
Oct 17, 2018

Study contacts

Mary T Bessesen, MD
principal investigator · Veterans Affairs Eastern Colorado Healthcare System

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion